Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.68 |
| ▸ | PPARD | Q03181 | 3/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.34 |
| ▸ | PPARA | Q07869 | 2/20 | 0.33 |
| ▸ | PPARG | P37231 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | CETP | P11597 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14797071 | 0.92 | S1PR1 (0.71) | S1PR1PPARDFFAR1PTPN1PPARA | |
| SCHEMBL14796988 | 0.91 | S1PR1 (0.70) | S1PR1PPARDFFAR1PTPN1PPARA | |
| SCHEMBL14797179 | 0.89 | S1PR1 (0.79) | S1PR1PPARDFFAR1PTPN1PPARA | |
| SCHEMBL14797099 | 0.89 | S1PR1 (0.68) | S1PR1PPARDFFAR1PTPN1PPARA | |
| SCHEMBL2222826 | 0.89 | S1PR1 (0.73) | S1PR1PPARDFFAR1PTPN1PPARA | |
| SCHEMBL2222592 | 0.88 | S1PR1 (0.81) | S1PR1PPARDFFAR1PTPN1PPARA | |
| SCHEMBL14797066 | 0.88 | S1PR1 (0.77) | S1PR1PPARDFFAR1PTPN1PPARA | |
| SCHEMBL14797326 | 0.86 | S1PR1 (0.64) | S1PR1PPARDPTPN1PPARAPPARG | |
| SCHEMBL2223368 | 0.86 | S1PR1 (0.83) | S1PR1PPARDFFAR1PTPN1PPARA | |
| SCHEMBL14797164 | 0.85 | S1PR1 (0.73) | S1PR1PPARDFFAR1PTPN1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846692-B2 | Carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring | SANOFI (FR) | 2014-09-30 | — | — | US | disclosed |
| US-20130079358-A1 | CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI (FR) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079358-A1 | CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING | OXGR1, EDNRA, EDF1 | S1PR1 129/4885PPARD 370/4885FFAR1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.